Clinical Trial Update: Weekly Paclitaxel With or Without Pazopanib in Platinum Resistant or Refractory Ovarian Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating weekly paclitaxel with or without pazopanib in platinum-resistant or refractory ovarian cancer has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Cancer

Drugs mentioned

• PACLITAXEL (PACLITAXEL)
• Pazopanib (Pazopanib)

Snippet

Sponsor: National Cancer Institute, Naples | Conditions: Ovarian Cancer | Phase 2 | Status: COMPLETED